Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have
pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3),
node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+)
(estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal
growth factor receptor 2 (HER2) negative or hormone receptor-negative (HR-)
(estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal
growth factor receptor 2 (HER2) negative/triple-negative breast cancer.